JP2021512151A5 - - Google Patents
Info
- Publication number
- JP2021512151A5 JP2021512151A5 JP2020561589A JP2020561589A JP2021512151A5 JP 2021512151 A5 JP2021512151 A5 JP 2021512151A5 JP 2020561589 A JP2020561589 A JP 2020561589A JP 2020561589 A JP2020561589 A JP 2020561589A JP 2021512151 A5 JP2021512151 A5 JP 2021512151A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024047473A JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620545P | 2018-01-23 | 2018-01-23 | |
| US62/620,545 | 2018-01-23 | ||
| PCT/US2019/014748 WO2019147670A1 (en) | 2018-01-23 | 2019-01-23 | B7-h4 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024047473A Division JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512151A JP2021512151A (ja) | 2021-05-13 |
| JP2021512151A5 true JP2021512151A5 (enExample) | 2022-01-31 |
Family
ID=67396234
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561589A Pending JP2021512151A (ja) | 2018-01-23 | 2019-01-23 | Ｂ７−ｈ４抗体およびその使用方法 |
| JP2024047473A Pending JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024047473A Pending JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12286478B2 (enExample) |
| EP (1) | EP3743447B1 (enExample) |
| JP (2) | JP2021512151A (enExample) |
| KR (1) | KR20200112913A (enExample) |
| CN (2) | CN112566934B (enExample) |
| AU (1) | AU2019211326B2 (enExample) |
| BR (1) | BR112020014929A2 (enExample) |
| CA (1) | CA3089469A1 (enExample) |
| DK (1) | DK3743447T3 (enExample) |
| ES (1) | ES2980171T3 (enExample) |
| WO (1) | WO2019147670A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112566934B (zh) | 2018-01-23 | 2024-09-17 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
| KR102716165B1 (ko) * | 2019-03-21 | 2024-10-15 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | 항-b7s1 폴리펩티드 및 이의 용도 |
| JP7726534B2 (ja) * | 2020-06-30 | 2025-08-20 | 諾納生物（蘇州）有限公司 | 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途 |
| MX2023008000A (es) | 2021-01-04 | 2023-07-13 | Mersana Therapeutics Inc | Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos. |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| WO2025128735A2 (en) * | 2023-12-11 | 2025-06-19 | Nextcure, Inc. | B7-h4 antibody-drug conjugates and methods of use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5190929A (en) | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2000012758A1 (en) | 1998-09-02 | 2000-03-09 | Diadexus Llc | A novel method of diagnosing, monitoring, staging, imaging and treating various cancers |
| US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US7888477B2 (en) | 1998-12-17 | 2011-02-15 | Corixa Corporation | Ovarian cancer-associated antibodies and kits |
| US6891030B2 (en) | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US7052694B2 (en) | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| WO2004101756A2 (en) | 2003-05-09 | 2004-11-25 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| US20070166281A1 (en) | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CA2611861C (en) | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment of persistent infections |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US20070243184A1 (en) | 2005-11-08 | 2007-10-18 | Steven Fischkoff | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
| US20070202077A1 (en) | 2005-12-02 | 2007-08-30 | Brodsky Robert A | Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders |
| KR101523391B1 (ko) | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| EP2124998B8 (en) | 2006-12-27 | 2015-05-06 | The Johns Hopkins University | Methods for detecting inflammation and auto-immune diseases |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| CL2008003526A1 (es) | 2007-11-30 | 2010-01-11 | Medarex Inc | Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer. |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| CA2772204A1 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2014044738A1 (en) | 2012-09-21 | 2014-03-27 | Sanofi | Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators |
| CA2894879A1 (en) * | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| JP6436965B2 (ja) * | 2013-03-14 | 2018-12-12 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及びイムノコンジュゲート |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US10626176B2 (en) * | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
| CN112566934B (zh) | 2018-01-23 | 2024-09-17 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
-
2019
- 2019-01-23 CN CN201980021260.8A patent/CN112566934B/zh active Active
- 2019-01-23 BR BR112020014929-2A patent/BR112020014929A2/pt unknown
- 2019-01-23 CA CA3089469A patent/CA3089469A1/en active Pending
- 2019-01-23 WO PCT/US2019/014748 patent/WO2019147670A1/en not_active Ceased
- 2019-01-23 US US16/964,133 patent/US12286478B2/en active Active
- 2019-01-23 AU AU2019211326A patent/AU2019211326B2/en active Active
- 2019-01-23 ES ES19743902T patent/ES2980171T3/es active Active
- 2019-01-23 JP JP2020561589A patent/JP2021512151A/ja active Pending
- 2019-01-23 EP EP19743902.9A patent/EP3743447B1/en active Active
- 2019-01-23 KR KR1020207024024A patent/KR20200112913A/ko not_active Ceased
- 2019-01-23 DK DK19743902.9T patent/DK3743447T3/da active
- 2019-01-23 CN CN202411212034.7A patent/CN119097699A/zh active Pending
-
2024
- 2024-03-25 JP JP2024047473A patent/JP2024075721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512151A5 (enExample) | ||
| Jin et al. | Emerging new therapeutic antibody derivatives for cancer treatment | |
| CN112739379B (zh) | 包含OX40抗原结合位点的Fc结合片段 | |
| TWI676681B (zh) | 具抗原專一性的t細胞及其用途 | |
| JP2022512653A5 (enExample) | ||
| JP2021531754A5 (enExample) | ||
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| HRP20230528T1 (hr) | Bispecifične molekule t stanica aktivirane proteazom | |
| JP2020501531A5 (enExample) | ||
| US11993655B2 (en) | Anti-PD-L1 antibody and use thereof | |
| JP2019524693A5 (enExample) | ||
| JP2022512043A5 (enExample) | ||
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| CN112111012B (zh) | 共价多特异性抗体 | |
| KR20200092301A (ko) | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 | |
| WO2021216468A1 (en) | Human tigit specific single domain antibodies and methods of use | |
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP2023511898A5 (enExample) | ||
| CA3155293A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| JP2016529213A5 (enExample) | ||
| JP2023504733A5 (enExample) | ||
| JP2018525347A (ja) | 癌免疫療法に使用するための二重特異性抗体 | |
| CN117480178A (zh) | 嵌合FC-α受体及其用途 | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JP2024542164A5 (enExample) |